drug
upadacitinib
Marketedupdated 3mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.
all catalysts(3)
Trials studying upadacitinib
- phase3Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- phase3Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- phase3A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
- phase1A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
- phase1A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
- phase3A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- phase3A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
- phase3Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 26, 2027
254 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Oct 17, 2036compositionUS 10981923
- Oct 17, 2036compositionUS 11186584
- Oct 17, 2036compositionUS 11661425
- Oct 17, 2036compositionUS 11680069
- Oct 17, 2036compositionUS 11718627
- Oct 17, 2036compositionUS 11773105
- Oct 17, 2036compositionUS 12110298
- Oct 17, 2036method-of-use (U-3945)US 12365689
- Oct 17, 2036compositionUS 9951080
- Aug 16, 2033compositionUS RE47221
- Jan 15, 2031compositionUS 89626294.4y
FDA exclusivities (2)
- Apr 26, 2031ODE-481Orphan Drug (7y)4.7y
- Apr 26, 2027NPNP254d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that